Search

Your search keyword '"AF Stättermayer"' showing total 146 results
Start Over Author "AF Stättermayer"
146 results on '"AF Stättermayer"'

6. Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease

Author

Michael Trauner, Alexander Stadlmann, Ernst Eigenbauer, Thomas Szekeres, Rodrig Marculescu, AF Stättermayer, Katharina Lampichler, Thomas Reiberger, Andrea Beer, Mattias Mandorfer, Benedikt Simbrunner, Katharina Wöran, Bernhard Scheiner, David Bauer, Rafael Paternostro, Theresa Bucsics, Philipp Schwabl, and Matthias Pinter

Subjects
Liver Cirrhosis, Placental growth factor, medicine.medical_specialty, Cirrhosis, Portal venous pressure, medicine.medical_treatment, Portal hypertensive gastropathy, Liver transplantation, Chronic liver disease, Severity of Illness Index, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Hypertension, Portal, medicine, Humans, Prospective Studies, Placenta Growth Factor, Hepatology, business.industry, Middle Aged, medicine.disease, Portal Pressure, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Portal hypertension, Female, 030211 gastroenterology & hepatology, business, Biomarkers
Abstract

Experimental data indicates that placental growth factor (PLGF) is involved in the pathophysiology of portal hypertension (PH) due to advanced chronic liver disease (ACLD). We investigated serum levels of PLGF and its "scavenger", the receptor soluble fms-like tyrosine kinase-1 (sFLT1, or sVEGFR1), in ACLD patients with different severity of PH and portal-hypertensive gastropathy (PHG).PLGF and sVEGFR1 were measured in ACLD patients with hepatic venous pressure gradient (HVPG) ≥6 mmHg (n = 241) and endoscopic evaluation of PHG (n = 216). Patients with pre-/posthepatic PH, TIPS, liver transplantation and hepatocellular carcinoma were excluded.Thirty-two (13%) patients had HVPG 6-9 mmHg, 128 (53%) 10-19 mmHg and 81 (34%) ≥20 mmHg; 141 (59%) had decompensated ACLD (dACLD). PLGF (median 17.2 vs. 20.8 vs. 22.4 pg/mL; p = 0.002), sVEGFR1 (median 96.0 vs. 104.8 vs. 119.3 pg/mL; p 0.001) levels increased across HVPG strata, while PLGF/sVEGFR1 ratios remained similar (0.19 vs. 0.20 vs. 0.18 pg/mL; p = 0.140). The correlation between PLGF and HVPG was weak (Rho = 0.190,95%CI 0.06-0.31; p = 0.003), and the PLGF/sVEGFR1 ratio did not correlate with HVPG (p = 0.331). The area-under-the-receiver operating characteristics (AUROC) for PLGF to detect clinically significant PH (CSPH;i.e. HVPG ≥ 10 mmHg) yielded only 0.688 (0.60-0.78; p 0.001). When compared to ACLD patients without PHG, PLGF levels (20 without vs. 21.4 with mild vs. 17.1 pg/mL with severe PHG, respectively; p = 0.005) and PLGF/sVEGFR1 ratios (0.20 vs. 0.19 vs. 0.17; p = 0.076) did not increase with mild and severe PHG.While PLGF levels tended to increase with severity of PH, the PLGF/sVEGFR1 ratio remained stable across HVPG strata. Neither PLGF nor the PLGF/sVEGFR1 ratio had diagnostic value for prediction of CSPH. The severity of PHG was also not associated with stepwise increases in PLGF levels or PLGF/sVEGFR1 ratio.

Published
2021

7. Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis

Author

Mattias Mandorfer, Rafael Paternostro, Peter Quehenberger, AF Stättermayer, Benedikt Simbrunner, Alexander Stadlmann, David Bauer, Theresa Bucsics, Philipp Schwabl, Thomas Reiberger, Georg Semmler, Bernhard Scheiner, Ernst Eigenbauer, Michael Trauner, Matthias Pinter, and Rodrig Marculescu

Subjects
Liver Cirrhosis, Male, 0301 basic medicine, Vitamin, medicine.medical_specialty, Cirrhosis, Portal venous pressure, medicine.medical_treatment, Hepatic venous pressure gradient, Liver transplantation, Chronic liver disease, Severity of Illness Index, Gastroenterology, 03 medical and health sciences, Liver disease, chemistry.chemical_compound, 0302 clinical medicine, ACLD, Internal medicine, Hypertension, Portal, medicine, Humans, Vitamin A, 030109 nutrition & dietetics, Hepatology, business.industry, Liver Neoplasms, Middle Aged, medicine.disease, Portal Pressure, chemistry, Portal hypertension, Original Article, Female, 030211 gastroenterology & hepatology, business, Hepatic decompensation
Abstract

Background and Aims The liver plays a key role in the storage, metabolism and homeostasis of fat-soluble vitamins. We investigated the relation of Vitamin(Vit)A/D/E serum levels with severity of liver disease and portal hypertension (PHT). Methods VitA/D/E serum levels were assessed in 234 patients with advanced chronic liver disease (ACLD, i.e. hepatic venous pressure gradient [HVPG] ≥ 6 mmHg). Patients with hepatocellular carcinoma, pre-/post-hepatic PHT, TIPS or liver transplantation were excluded. Results Most patients were male (n = 153; 65%) with a median age of 57.6 (49.7–64.5) years. Thirty-two (14%) patients had HVPG 6–9 mmHg, 66 (28%) 10-15 mmHg, and 136 (58%) ≥ 16 mmHg, respectively. VitD deficiency (25-OH-vitamin-D p 1.05 µmol/L) VitA levels, while 58 (25%) had mild (0.70–1.04 µmol/L), 71 (30%) moderate (0.35–0.69 µmol/L), and 42(18%) severe(Rho = −0.409), CTP score (Rho = −0.646), and serum bile acid levels (Rho = −0.531; all p p p p = 0.001) and elevated bile acid levels(>10 µmol/L; OR 3.62; 95%CI 1.61–8.14; p = 0.002) were independently associated with VitA deficiency. Conclusion VitA and VitD but not VitE deficiencies are highly prevalent in ACLD. VitA deficiency strongly correlates with hepatic dysfunction, PHT and bile acid levels and is associated with decompensated ACLD. Trial registration number NCT03267615.

Published
2020

8. Von Willebrand Factor (VWF) propeptide levels are similarly accurate for assessing portal hypertension as compared to VWF antigen

Author

M. Trauner, Rodrig Marculescu, I Villesen, Bernhard Scheiner, D Leeming, Philipp Schwabl, Benedikt Simbrunner, Matthias Pinter, AF Stättermayer, Peter Quehenberger, Thomas Reiberger, Mattias Mandorfer, M Karsdal, David Bauer, and Rafael Paternostro

Subjects
medicine.medical_specialty, Endocrinology, Antigen, Von Willebrand factor, biology, business.industry, Internal medicine, biology.protein, medicine, Portal hypertension, Protein precursor, business, medicine.disease
Published
2021

9. Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease

Author

M. Trauner, Mattias Mandorfer, Lorenz Balcar, Peter Quehenberger, AF Stättermayer, Bernhard Scheiner, RJ Nussbaumer, Rafael Paternostro, Matthias Pinter, Georg Semmler, Benedikt Simbrunner, Lukas Hartl, Thomas Reiberger, Douglas C. Bauer, Katharina Pomej, Mathias Jachs, and J Weinzierl

Subjects
medicine.medical_specialty, business.industry, Internal medicine, medicine, In patient, Clinical significance, business, Chronic liver disease, medicine.disease, Gastroenterology, Von Willebrand factor Antigen
Published
2021

10. Acute haemodynamic response to intravenous propranolol predicts decompensation and mortality in patients with cirrhosis

Author

M. Trauner, Benedikt Simbrunner, Douglas C. Bauer, Mattias Mandorfer, Mathias Jachs, AF Stättermayer, Thomas Reiberger, Rafael Paternostro, Lukas Hartl, Bernhard Scheiner, Philipp Schwabl, and Benedikt Silvester Hofer

Subjects
medicine.medical_specialty, Cirrhosis, Haemodynamic response, business.industry, Internal medicine, Cardiology, medicine, In patient, Decompensation, Propranolol, medicine.disease, business, medicine.drug
Published
2021

11. Von Willebrand factor for outcome prediction within different clinical stages of advanced chronic liver disease

Author

Georg Semmler, M. Trauner, Lukas Hartl, Bernhard Scheiner, Peter Quehenberger, Matthias Pinter, Thomas Reiberger, Douglas C. Bauer, Mattias Mandorfer, AF Stättermayer, Benedikt Simbrunner, Mathias Jachs, Lorenz Balcar, and Rafael Paternostro

Subjects
medicine.medical_specialty, Von Willebrand factor, biology, business.industry, Internal medicine, medicine, biology.protein, Chronic liver disease, medicine.disease, Outcome prediction, business, Gastroenterology
Published
2021

12. Factor VIII/protein C ratio independently predicts liver-related events but does not reflect the hypercoagulable state in patients with advanced-chronic liver disease

Author

M. Trauner, RJ Nussbaumer, Mathias Jachs, Lorenz Balcar, Ton Lisman, Georg Semmler, Bernhard Scheiner, AF Stättermayer, Benedikt Simbrunner, Matthias Pinter, J Weinzierl, Peter Quehenberger, Douglas C. Bauer, Rafael Paternostro, Thomas Reiberger, Mattias Mandorfer, and Lukas Hartl

Subjects
medicine.medical_specialty, business.industry, Internal medicine, medicine, In patient, Chronic liver disease, medicine.disease, business, Gastroenterology, Protein C, medicine.drug
Published
2021

13. Prediction of hepatocellular carcinoma after sustained virologic response in patients with compensated advanced chronic liver disease

Author

Joan Genescà, Philipp Schwabl, Thomas Reiberger, AF Stättermayer, Sergio Rodríguez-Tajes, Peter Ferenci, Benedikt Simbrunner, Lopez S Alonso, David Chromy, Mattias Mandorfer, Sabela Lens, M. Trauner, David Bauer, EL Meyer, ML Manzano, Alberto Zanetto, Rafael Bañares, Michael Schwarz, Francesco Paolo Russo, Karin Kozbial, M Gschwantler, S Hametner-Schreil, R Schöfl, Matthias Pinter, Mònica Pons, Georg Semmler, and Bernhard Scheiner

Subjects
medicine.medical_specialty, business.industry, Internal medicine, Hepatocellular carcinoma, Virologic response, medicine, In patient, Chronic liver disease, medicine.disease, business, Gastroenterology
Published
2021

14. NSBB-associated VWF-decreases in decompensated cirrhosis indicate a reduced risk of further decompensation, ACLF, and death

Author

Lukas Hartl, Mattias Mandorfer, Ernst Eigenbauer, Douglas C. Bauer, M. Trauner, AF Stättermayer, Mathias Jachs, Matthias Pinter, Philipp Schwabl, Benedikt Simbrunner, Rafael Paternostro, Thomas Reiberger, Bernhard Scheiner, and Peter Quehenberger

Subjects
medicine.medical_specialty, Reduced risk, business.industry, Internal medicine, Cardiology, medicine, Decompensation, Decompensated cirrhosis, business
Published
2021

15. Impact of patatin‐like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension

Author

Philipp Schwabl, Bernhard Scheiner, Douglas C. Bauer, Thomas Reiberger, Arnulf Ferlitsch, Peter Ferenci, Markus Peck-Radosavljevic, M. Trauner, Heinz Zoller, AF Stättermayer, Mattias Mandorfer, Rafael Paternostro, and Benedikt Schaefer

Subjects
0301 basic medicine, Adult, Male, medicine.medical_specialty, Genotype, Portal venous pressure, Gastroenterology, Polymorphism, Single Nucleotide, Hepatic Decompensation in Portal Hypertension, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Hypertension, Portal, medicine, Humans, Pharmacology (medical), Genetic Predisposition to Disease, Longitudinal Studies, Survival rate, Aged, Retrospective Studies, Hepatology, business.industry, Fatty liver, Membrane Proteins, Hepatitis C, Lipase, Hepatitis C, Chronic, Middle Aged, medicine.disease, Hepatic stellate cell activation, Fatty Liver, Survival Rate, 030104 developmental biology, Cross-Sectional Studies, Portal hypertension, 030211 gastroenterology & hepatology, Female, Original Article, Steatosis, business, Viral hepatitis, Liver Failure
Abstract

Background The rs738409 C>G p.I148M variant in the patatin-like phospholipase domain containing 3 (PNPLA3)-gene promotes triglyceride accumulation in hepatocytes and hepatic stellate cell activation and has previously been linked to hepatic steatosis/liver fibrosis. Aim To investigate its impact on hepatic decompensation and (liver-related) mortality in patients who had already developed portal hypertension. Moreover, we assessed its link with hepatic steatosis as evaluated by controlled attenuation parameter. Methods We performed a retrospective analysis in prospectively characterised patients with viral hepatitis/fatty liver disease-induced portal hypertension (hepatic venous pressure gradient [HVPG] ≥ 6 mm Hg) diagnosed at the Medical University of Vienna who underwent HVPG measurement (until 2013; n = 372; longitudinal study) or simultaneous HVPG and controlled attenuation parameter measurement (2014-2017; n = 153; cross-sectional study). Results While survival was similar between PNPLA3-C/C and -C/G patients, we observed substantially increased mortality in PNPLA3-G/G patients. PNPLA3-G/G had no impact on mortality in the subgroup of patients with viral hepatitis; however, we observed a strong independent association between PNPLA3-G/G and hepatic decompensation (adjusted subdistribution hazard ratio [aSHR]: 2.1, 95% confidence interval [95% CI]: 1.1-4; P = 0.024) as well as mortality (overall: aSHR: 2.2, 95% CI: 1.22-3.98; P = 0.009; liver-related: aSHR: 2.2, 95% CI: 1.08-4.46; P = 0.029) in patients with fatty liver disease. Interestingly, even in the subgroup of patients who had already progressed to clinically significant portal hypertension (HVPG ≥ 10 mm Hg), PNPLA3-G/G substantially increased mortality (aSHR: 2.33, 95% CI: 1.27-4.29; P = 0.006). PNPLA3-genotype had no influence on controlled attenuation parameter or the prevalence of values ≥248 dB/m. Conclusion PNPLA3-G/G-genotype seems to double the risks of hepatic decompensation and (liver-related) mortality in patients with portal hypertension due to fatty liver disease. Further studies are warranted to investigate potential underlying pathophysiological mechanisms unrelated to hepatic steatosis.

Published
2018

16. Long-term follow up of patients with advanced chronic hepatitis C after successful treatment with interferon/ribavirin-free combination of direct acting antivirals

Author

Michael Gschwantler, M Srasser, Rudolf E. Stauber, Remy Schwarzer, Heinz Zoller, AF Stättermayer, Sandra Beinhardt, Andreas Maieron, Karin Kozbial, R Al-Zoairy, Peter Ferenci, S Moser, Harald Hofer, Christian Datz, Petra Steindl-Munda, and Hermann Laferl

Subjects
medicine.medical_specialty, business.industry, Long term follow up, Ribavirin, Gastroenterology, DIRECT ACTING ANTIVIRALS, Virology, chemistry.chemical_compound, chemistry, Chronic hepatitis, Interferon, Internal medicine, Medicine, business, medicine.drug
Published
2017

17. The HSD17B13:TA (rs72613567) splice variant protects against severity of non-alcoholic fatty liver disease but not fibrosis

Author

M. Trauner, P Munda, Stefan Traussnigg, Omar Keritam, Peter Ferenci, Judith Stift, Rafael Paternostro, Gerald W. Prager, Emina Halilbasic, Katharina Staufer, and AF Stättermayer

Subjects
medicine.medical_specialty, Fibrosis, business.industry, Internal medicine, Fatty liver, Alternative splicing, medicine, Non alcoholic, Disease, medicine.disease, business, Gastroenterology
Published
2019

18. Impact of farnesoid X receptor (FXR) polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension

Author

Bernhard Scheiner, Douglas C. Bauer, Peter Ferenci, AF Stättermayer, Benedikt Simbrunner, Matthias Pinter, Georg Semmler, Rafael Paternostro, Mattias Mandorfer, Thomas Reiberger, Theresa Bucsics, Philipp Schwabl, and M. Trauner

Subjects
medicine.medical_specialty, business.industry, Internal medicine, medicine, Portal hypertension, Farnesoid X receptor, medicine.disease, business, Gastroenterology, Hepatic decompensation
Published
2019

19. Limited diagnostic performance of controlled attenuation parameter for assessing hepatic steatosis in patients with advanced chronic liver disease and portal hypertension

Author

Mattias Mandorfer, Matthias Pinter, Philipp Schwabl, AF Stättermayer, Georg Semmler, M. Trauner, Thomas Reiberger, Judith Stift, Bernhard Scheiner, and Rafael Paternostro

Subjects
medicine.medical_specialty, business.industry, Internal medicine, medicine, Portal hypertension, In patient, Steatosis, business, medicine.disease, Chronic liver disease, Gastroenterology
Published
2018

20. Transjugular liver biopsy performed by Hepatologists trained in hepatic venous pressure gradient measurements is safe and provides important diagnostic and prognostic information

Author

Rafael Paternostro, Markus Peck-Radosavljevic, Georg Semmler, AF Stättermayer, Remy Schwarzer, Judith Stift, Bernhard Scheiner, C Walzel, Matthias Pinter, Arnulf Ferlitsch, Mattias Mandorfer, Philipp Schwabl, Thomas Reiberger, and M. Trauner

Subjects
medicine.medical_specialty, business.industry, Portal venous pressure, Medicine, Transjugular liver biopsy, Radiology, business
Published
2018

22. Real world experience of retreatment of chronic hepatitis C patients who failed IFN-free DAA therapy

Author

Ludwig Kramer, S Hametner, Michael Strasser, Heinz Zoller, AF Stättermayer, M. Trauner, Karin Kozbial, Harald Hofer, Hermann Laferl, Rudolf E. Stauber, Sandra Beinhardt, Michael Gschwantler, C. Datz, Andreas Maieron, Benedikt Schaefer, P. Munda, A. Hayat-Khayyati, Ivo Graziadei, Peter Ferenci, and R Al-Zoairy

Subjects
medicine.medical_specialty, Hepatology, Chronic hepatitis, business.industry, Internal medicine, medicine, business, Ifn free, Gastroenterology
Published
2018

23. Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral

Author

M. Dulic, Harald Hofer, Karoline Rutter, Andreas Maieron, AF Stättermayer, Heidemarie Holzmann, Robert Strassl, Petra Steindl-Munda, Peter Ferenci, Sandra Beinhardt, Hermann Laferl, Thomas-Matthias Scherzer, and Michael Gschwantler

Subjects
Simeprevir, medicine.medical_specialty, Hepatology, business.industry, Ribavirin, Balapiravir, Danoprevir, Gastroenterology, virus diseases, Telaprevir, Surgery, chemistry.chemical_compound, chemistry, Internal medicine, Genotype, Faldaprevir, Medicine, Pharmacology (medical), business, Mericitabine, medicine.drug
Abstract

BACKGROUND The introduction of direct-acting anti-virals has increased sustained virological response (SVR) rates in chronic hepatitis C genotype 1 infection. At present, data on long-term durability of viral eradication after successful triple therapy are lacking. AIM To evaluate the long-term durability of viral eradication in patients treated with triple therapy, including direct-acting anti-virals. METHODS Patients who participated in randomised, controlled trials or an extended access programme of treatment with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral (telaprevir, danoprevir, faldaprevir, simeprevir, mericitabine, balapiravir) were followed after achieving SVR. The median follow-up after the patients was 21 (range: 7-64) months. RESULTS One hundred and three patients with chronic hepatitis C genotype 1 infection [f/m: 34/69; GT-1b: 67 GT-1a: 34, GT-4: 2; mean age: 47.6 years (45.5-49.7; 95% CI)] achieving a SVR triple therapy were followed. Two cases of late relapses (2/103, 1.9%; 95% CI: 0.24-6.8) were observed. One patient was cirrhotic, both carried the genotype 1b and completed the prescribed treatment. The relapses occurred 8 and 12 months after cessation of anti-viral treatment. Cloning sequencing revealed identical sequence in both patients. Resistance analysis revealed no presence of viral resistance. CONCLUSION Like the SVR after peginterferon-α2/ribavirin combination treatment, HCV eradication after triple therapy remains durable after long-term follow-up.

Published
2013

24. Decrease of Hyperferritinemia in chronic Hepatitis C patients due to IFN/RBV free antiviral treatment

Author

P Munda, R Stern, Peter Ferenci, C Freissmuth, Harald Hofer, Sandra Beinhardt, AF Stättermayer, and Karin Kozbial

Subjects
03 medical and health sciences, 0302 clinical medicine, Chronic hepatitis, business.industry, Immunology, Gastroenterology, Medicine, 030211 gastroenterology & hepatology, 030212 general & internal medicine, Antiviral treatment, business, Virology
Published
2016

25. Safety and efficacy of IFN/RBV-free DAA-based regimens in HCV-recurrence after Orthotopic Liver Transplantation

Author

Ivo Graziadei, R Al-Zoairy, Peter Ferenci, Andreas Maieron, Harald Hofer, R Stern, Rudolf E. Stauber, Karin Kozbial, M. Trauner, Michael Strasser, Heinz Zoller, AF Stättermayer, and Sandra Beinhardt

Subjects
medicine.medical_specialty, Orthotopic liver transplantation, business.industry, Internal medicine, Gastroenterology, Medicine, Hcv recurrence, business, Surgery
Published
2016

26. Long-term impact of achieving sustained virologic response(SVR)by IFN-free DAA treatment in patients with advanced liver disease

Author

AF Stättermayer, S Moser, R Stern, Harald Hofer, Hermann Laferl, Peter Ferenci, R Al-Zoairy, Karin Kozbial, C Freissmuth, Andreas Maieron, Michael Gschwantler, Sandra Beinhardt, and Remy Schwarzer

Subjects
Oncology, medicine.medical_specialty, business.industry, Gastroenterology, medicine.disease, Ifn free, Term (time), Liver disease, Internal medicine, Virologic response, Immunology, Medicine, In patient, business
Published
2016

27. Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/HCV-coinfected patients with advanced liver disease

Author

David Chromy, S Steiner, Thomas Reiberger, Katharina Grabmeier-Pfistershammer, Theresa Bucsics, Markus Peck-Radosavljevic, Philipp Schwabl, Mattias Mandorfer, Maximilian C. Aichelburg, AF Stättermayer, and Michael Trauner

Subjects
Daclatasvir, Sofosbuvir, business.industry, Interferon free, Gastroenterology, medicine.disease, Virology, 03 medical and health sciences, Liver disease, 0302 clinical medicine, Virologic response, Immunology, Medicine, 030211 gastroenterology & hepatology, 030212 general & internal medicine, business, medicine.drug
Published
2016

28. Association between improved liver function and selenium depends on C718T polymorphism in 3’- untranslated region of glutathione peroxidase 4 and in humans

Author

Thomas Reiberger, Elisabeth Eder, M. Seif, M. Trauner, Bernhard K. Keppler, Peter Ferenci, Harald Hofer, G. Köllensperger, Thomas-Matthias Scherzer, Sandra Beinhardt, Sarah Theiner, AF Stättermayer, C. Willheim, Markus Peck-Radosavljevic, and N. Rohr-Udilova

Subjects
Hepatology, chemistry, Polymorphism (materials science), Biochemistry, Three prime untranslated region, chemistry.chemical_element, Liver function, Biology, GPX4, Molecular biology, Selenium
Published
2017

32. Seroprevalence of Hepatitis E Virus in patients with Autoimmune Hepatitis

Author

M Eder, Harald Hofer, Karin Kozbial, M. Trauner, Sandra Beinhardt, AF Stättermayer, C Freissmuth, Robert Strassl, Heidemarie Holzmann, and Peter Ferenci

Subjects
Hepatitis E virus, business.industry, Immunology, Gastroenterology, Medicine, Seroprevalence, In patient, Autoimmune hepatitis, business, medicine.disease, medicine.disease_cause, Virology
Published
2015

33. The presence of a PNPLA3 (rs738409) single nucleotide polymorphism (SNP) is not associated with increased risk for fibrosis, portal hypertension, and hepatic steatosis in HIV/HCV-coinfected patients

Author

Peter Ferenci, Katharina Grabmeier-Pfistershammer, Berit A. Payer, M. Trauner, Markus Peck-Radosavljevic, Maximilian C. Aichelburg, Bernhard Scheiner, AF Stättermayer, Mattias Mandorfer, Thomas Reiberger, and Philipp Schwabl

Subjects
Increased risk, Fibrosis, Immunology, Gastroenterology, medicine, Portal hypertension, SNP, Single-nucleotide polymorphism, Steatosis, Biology, medicine.disease
Published
2015

35. High prevalence of Vitamin D deficiency in patients with autoimmune Hepatitis: impact on clinical presentation and response to treatment

Author

M Eder, J Stift, Robert Strassl, C Freissmuth, Rodrig Marculescu, AF Stättermayer, Karin Kozbial, and Sandra Beinhardt

Subjects
Pediatrics, medicine.medical_specialty, High prevalence, business.industry, Gastroenterology, Autoimmune hepatitis, medicine.disease, Response to treatment, vitamin D deficiency, Immunology, Medicine, In patient, Presentation (obstetrics), business
Published
2015

36. Interferon-free Sofosbuvir containing treatment regimens in a real-life cohort of chronic Hepatitis C patients with cirrhosis

Author

Rudolf E. Stauber, M. Trauner, R Stern, Arnulf Ferlitsch, M Eder, Peter Ferenci, Karin Kozbial, Harald Hofer, Michael Strasser, Michael Gschwantler, Mattias Mandorfer, Heinz Zoller, AF Stättermayer, Sandra Beinhardt, S Hametner, C Freissmuth, S Moser, T Bamberger, Hermann Laferl, Andreas Maieron, Wolfgang Vogel, R Al-Zoairy, Ivo Graziadei, Robert Strassl, and Markus Peck-Radosavljevic

Subjects
medicine.medical_specialty, Cirrhosis, Sofosbuvir, business.industry, Treatment regimen, Interferon free, Gastroenterology, medicine.disease, Surgery, Chronic hepatitis, Internal medicine, Cohort, Medicine, business, medicine.drug
Published
2015

37. Interferon-free regimens overcome the effect of portal hypertension on virologic response

Author

Thomas Reiberger, Markus Peck-Radosavljevic, Karin Kozbial, M. Trauner, Philipp Schwabl, Remy Schwarzer, Sandra Beinhardt, Harald Hofer, Mattias Mandorfer, AF Stättermayer, Arnulf Ferlitsch, C Freissmuth, and Peter Ferenci

Subjects
medicine.medical_specialty, Endocrinology, business.industry, Internal medicine, Interferon free, Virologic response, Gastroenterology, medicine, Portal hypertension, medicine.disease, business
Published
2015

39. Effect of Fibrate-Add-On Treatment in Primary Biliary Cholangitis Patients with an Insufficient Response to Ursodeoxycholic Acid

Author

Emina Halilbasic, AF Stättermayer, R Stern, Harald Hofer, Peter Ferenci, Karin Kozbial, Sandra Beinhardt, M. Trauner, and C Freissmuth

Subjects
medicine.medical_specialty, Add on treatment, Primary (chemistry), Hepatology, medicine.drug_class, business.industry, Internal medicine, medicine, Fibrate, business, Gastroenterology, Ursodeoxycholic acid, medicine.drug
Published
2016

40. P0740 : Usefulness of interferon LAMBDA4-, HLA class II-polymorphism and killer-immunglobulin -like receptor-2DL3:C1/C1 to predict spontaneous clearance of acute hepatitis C virus infection

Author

G. Fischer, Michael Gschwantler, AF Stättermayer, Harald Hofer, Peter Ferenci, Sandra Beinhardt, Emina Dulic-Lakovic, Berit A. Payer, Rudolf E. Stauber, Andreas Maieron, Mattias Mandorfer, C. Datz, and F. Huber

Subjects
Hla class ii, Hepatology, business.industry, Interferon, Immunology, Medicine, Acute hepatitis C, business, Receptor, Virology, Virus, medicine.drug
Published
2015

41. Safety and Efficacy of IFN&RBV-Free DAA-Based Regimens in HCV-Recurrence after Orthotopic Liver Transplantation

Author

Harald Hofer, Rudolf E. Stauber, Sandra Beinhardt, Heinz Zoller, AF Stättermayer, M. Peck-Radosaljevic, R Al-Zoairy, R Stern, Peter Ferenci, Andreas Maieron, C Freissmuth, Michael Strasser, Wolfgang Vogel, Katharina Staufer, Karin Kozbial, and M. Trauner

Subjects
medicine.medical_specialty, Hepatology, Orthotopic liver transplantation, business.industry, Internal medicine, Medicine, Hcv recurrence, business, Gastroenterology
Published
2016

45. IL28B polymorphism is associated with acute presentation and spontaneous clearance in hepatitis C virus infection

Author

M Imre, Thomas-Matthias Scherzer, Peter Ferenci, Heidemarie Holzmann, Hermann Laferl, Karoline Rutter, Michael Gschwantler, Andreas Maieron, AF Stättermayer, Michael Strasser, Petra Steindl-Munda, Harald Hofer, Rudolf E. Stauber, Martin Bischof, and Sandra Beinhardt

Subjects
business.industry, Hepatitis C virus, Immunology, Gastroenterology, medicine, Presentation (obstetrics), medicine.disease_cause, business, Virology, Il28b polymorphism
Published
2010

46. P1165 : High seroprevalence of hepatitis E in patients with autoimmune hepatitis

Author

Peter Ferenci, M. Trauner, AF Stättermayer, Karin Kozbial, M Eder, Heidemarie Holzmann, Sandra Beinhardt, Harald Hofer, Robert Strassl, and C Freissmuth

Subjects
Hepatology, business.industry, Immunology, medicine, High seroprevalence, In patient, Autoimmune hepatitis, medicine.disease, Hepatitis E, business
Published
2015

47. P0191 : IFN-free regimens overcome the negative effect of portal hypertension on virologic response and viral kinetics in patients with cirrhosis

Author

Mattias Mandorfer, M. Trauner, Harald Hofer, Karin Kozbial, C Freissmuth, Arnulf Ferlitsch, AF Stättermayer, Markus Peck-Radosavljevic, Sandra Beinhardt, Peter Ferenci, Philipp Schwabl, Thomas Reiberger, and Remy Schwarzer

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, education, Hemodynamics, medicine.disease, Ifn free, Gastroenterology, Viral kinetics, humanities, Virologic response, Internal medicine, medicine, Portal hypertension, In patient, business
Abstract

P0191 IFN-FREE REGIMENS OVERCOME THE NEGATIVE EFFECT OF PORTAL HYPERTENSION ON VIROLOGIC RESPONSE AND VIRAL KINETICS IN PATIENTS WITH CIRRHOSIS M. Mandorfer, K. Kozbial, C. Freissmuth, P. Schwabl, A.F. Stattermayer, T. Reiberger, S. Beinhardt, R. Schwarzer, M. Trauner, A. Ferlitsch, H. Hofer, M. Peck-Radosavljevic, P. Ferenci, on behalf of Vienna Hepatic Hemodynamic Lab. Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria E-mail: mattias.mandorfer@meduniwien.ac.at

Published
2015

48. P0717 : The presence of a PNPLA3 (rs738409) single nucleotide polymorphism (SNP) is not associated with increased risk for fibrosis, portal hypertension, and hepatic steatosis in HIV/HCV-coinfected patients

Author

Maximilian C. Aichelburg, Markus Peck-Radosavljevic, Thomas Reiberger, Mattias Mandorfer, Philipp Schwabl, AF Stättermayer, Katharina Grabmeier-Pfistershammer, Berit A. Payer, M. Trauner, Bernhard Scheiner, and Peter Ferenci

Subjects
medicine.medical_specialty, Hepatology, business.industry, Single-nucleotide polymorphism, medicine.disease, Gastroenterology, Increased risk, Fibrosis, Internal medicine, SNP, Medicine, Portal hypertension, Steatosis, business
Published
2015

49. P1083 VON WILLEBRAND FACTOR ANTIGEN (vWF-Ag): A NON-INVASIVE PREDICTOR OF TREATMENT RESPONSE AND SEVERE ADVERSE EVENTS IN HCV PATIENTS WITH DAA BASED TRIPLE THERAPY

Author

M. Trauner, Thomas Reiberger, Arnulf Ferlitsch, Peter Quehenberger, Peter Ferenci, Markus Peck-Radosavljevic, P. Salzl, Karoline Rutter, Monika Ferlitsch, Sandra Beinhardt, AF Stättermayer, Andreas Maieron, S Hametner, Harald Hofer, and A. Etschmaier

Subjects
Treatment response, Hepatology, business.industry, Non invasive, Immunology, Medicine, business, Adverse effect, Von Willebrand factor Antigen
Published
2014

50. 65 SAFETY OF TRIPLE THERAPY WITH TELAPREVIR OR BOCEPREVIR IN HEPATITIS C PATIENTS WITH ADVANCED LIVER DISEASE – PREDICTIVE FACTORS FOR SEPSIS

Author

Rudolf E. Stauber, Karoline Rutter, Peter Ferenci, Markus Peck-Radosavljevic, Harald Hofer, M. Dulic, AF Stättermayer, Andreas Maieron, Wolfgang Vogel, Michael Gschwantler, Ivo Graziadei, M. Trauner, and Arnulf Ferlitsch

Subjects
medicine.medical_specialty, Hepatology, business.industry, Hepatitis C, medicine.disease, Gastroenterology, Telaprevir, Sepsis, chemistry.chemical_compound, Liver disease, chemistry, Boceprevir, Internal medicine, medicine, business, medicine.drug
Published
2013

Catalog

Books, media, physical & digital resources
See catalog results